Prescient Therapeutics teams up with Peter MacCallum Cancer Centre to advance CAR-T cancer therapy

On August 14, 2020 Prescient Therapeutics (ASX: PTX) reported that it has moved closer to developing its unique CAR-T cancer technology after revealing a collaboration with the world-renowned Peter MacCallum Cancer Centre (Peter Mac) in Melbourne (Press release, Prescient Therapeutics, AUG 14, 2020, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-teams-up-with-peter-maccallum-cancer-centre-to-advance-car-t-cancer-therapy [SID1234565487]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration is expected to leverage Prescient’s proprietary CAR-T cancer therapy and extend its portfolio.

According to Prescient Therapeutics, it is the only ASX-listed stock with CAR-T technology, which is a type of cellular therapy that reprograms a cancer patient’s immune cells to recognise and destroy cancer.

Peter Mac’s professor Phil Darcy will lead the research, with Prescient to own any intellectual property arising from the program.

Prof Darcy said CAR-T therapy had shown "strong therapeutic activity" in certain haematological malignancies.

However, its impact on solid cancers hasn’t been as strong.

"The approach we are exploring with Prescient may reprogram the tumour microenvironment that results in significantly enhancing CAR-T cell anti-tumour activity," Prof Darcy added.

Cell therapy enhancements programs
The collaboration with Peter Mac adds to the Prescient’s current pipeline of cell therapy enhancements (CTE) programs.

Another CTE program is underway with Carina Biotech, with both this and the Peter Mac research aiming to generate technologies that can complement existing CAR-T approaches.

The company added the CTE research aims to develop efficacy and efficiency enhancements that appeal to third parties in the field that may incorporate the technology into their own programs under licence.

"We are working against time for many cancer patients so joining the world-leading experts in this field at Peter Mac will greatly enhance our collective efforts to advance these new treatments and get them to patients who will potentially benefit," Prescient chief executive officer Steven Yatomi-Clarke said.

"Prescient is the only ASX-listed company developing CAR-T programs and this is an important strategic initiative to complement our programs in CTE," he added.

Cancer therapy PTX-100
Today’s news of the Peter Mac research collaboration follows Prescient revealing earlier this week studies on its PTX-100 drug had advanced.

Phase 1b of PTX-100 is proceeding to the next dose level of 2,000mg/m2 after successful completion in the second cohort of 1,000mg/m2.

The three people in the second study were heavily pre-treated patients suffering from advanced pancreatic cancer, peripheral T cell lymphoma and angioimmunoblastic T-cell lymphoma.

Prescient’s PTX-100 is a Ras pathway inhibitor designed to ultimately lead to the death of cancer cells.

This phase 1b basket study aims to determine the safety, dose regimen and treatment schedule of PTX-100 as a single agent in several cancers where Ras and RhoA mutations are prevalent.

Analysis of the first cohort that received 500mg/m2 has shown stable disease and partial response in two patients.

Only ASX-listed Healthcare Company Developing CAR-T Programs- PTX Collaborates With Peter MacCallum Cancer Centre

On 14 August 2020, Prescient stock zoomed up by 6.667% to A$0.064 at AEST 2:12 PM after the Company reported a research collaboration with the world-class cell therapy institute Peter MacCallum Cancer Centre (Peter Mac) for developing innovative cell therapy technologies, including CAR-T technologies (Press release, Prescient Therapeutics, AUG 14, 2020, View Source;utm_medium=rss&utm_campaign=only-asx-listed-healthcare-company-developing-car-t-programs-ptx-collaborates-with-peter-maccallum-cancer-centre [SID1234565506]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of this research agreement, Prescient will own the IP (intellectual property) generated from the research program being led by Professor Phil Darcy of Peter Mac.

Melbourne-based Peter MacCallum Cancer Centre is an internationally recognised research and clinical leader in developing new therapies for cancer.

This is the second addition to the Cell Therapy Enhancement (CTE) Programs of Prescient Therapeutics. Prescient is already working with Carina Biotech and University of Adelaide on other CTE approaches.

Complementing the CTE programs, Prescient is also developing next-generation CAR-T therapies with its OmniCAR platform, following it announcement in late May 2020 that Prescient obtained key licenses from the University of Pennsylvania and Oxford University.

To Know More, Do Read: Impressive! Prescient Obtains Key Licenses for Next-Generation Immunotherapy Platform

Currently, Prescient Therapeutics is conducting a Share Purchase Plan (SPP) at 5.5c which closes on 20 August 2020 at AEST 5:00 PM. Click here to request personalised SPP forms.

Cell Therapy Enhancements Programs of Prescient

CAR-T is a cellular therapy that reprograms the immune cells of a cancer patient to identify and destroy cancer.

The research program, being undertaken in Professor Darcy’s laboratory at Melbourne-based Peter Mac, is an important addition to the Cell Therapy Enhancements (CTE) programs in the pipeline of Prescient.

On the same lines as the Cell Therapy Enhancements program that is underway with Carina Biotech, this research program aims to produce technologies complementing current CAR-T approaches.

The objective of Prescient’s CTE program is to develop efficacy as well as efficiency improvements that are relevant to 3rd parties in the cell therapy field (called CAR-T), which may incorporate these into their own programs under license.

Also Read: Get Acquainted with Prescient Therapeutics’ Next Generation Immunotherapy Platform

It is noteworthy to mention that Prescient will retain its previously built intellectual property and look to extend this portfolio by collaborating with world-renowned cancer centre Peter Mac.

Prescient Therapeutics CEO Steven Yatomi-Clarke stated that PTX is the only ASX-listed healthcare company developing CAR-T programs, and this is an important strategic initiative to complement programs of the Company in Cell Therapy Enhancements.

He also added-

Bottomline

Prescient has been progressing well in its cell therapy platform by obtaining two major licenses for developing innovative universal CAR Platform and now by collaborating with world-renowned Institute ‘Peter MacCallum Cancer Centre’. These developments drive Prescient to create innovative cell therapies for treating challenging cancers having unmet medical need.

These events demonstrate that Prescient Therapeutics is on a growth track backed by strong management in the most modern arena of cancer therapy.

Seneca Biopharma Reports 2020 Second Quarter Results

On August 14, 2020 Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, reported its financial results for the quarter ended June 30, 2020 (Press release, Neuralstem, AUG 14, 2020, View Source [SID1234563654]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Business Highlights for 2020 to date.

During the First Half of 2020, the Company achieved the following business milestones:

Completed offerings resulting in net proceeds of over $14.8 million.
Continued progress on both the Company’s out-licensing effort to partner NSI-566 and NSI-189 programs and initiative to in-license or acquire novel therapeutics.
Appointed of Matthew W. Kalnik, Ph.D. as President and Chief Operating Officer and Dane R. Saglio as Chief Financial Officer.
Affirmed guidance that data readout from the Company’s non-GCP Phase II trial evaluating NSI-566, for the treatment of chronic ischemic stroke, is expected during the second half of 2020.
Announced that as a result of feedback received from the FDA, Seneca believes that the existing Phase 1 and 2 trial results support moving into a Phase 3 clinical study for ALS.
Completion of the Company’s stem cell manufacturing facility in Suzhou, China which will be used to manufacture NSI-566 for clinical trials within China.
Financial Results for the Quarter Ended June 30, 2020

Cash Position and Liquidity: At June 30, 2020, cash was approximately $15.8 million as compared to approximately $10 million at March 31, 2020. The increase in cash is attributed to the May 2020 warrant exercises and registered direct offering.

Operating Loss: Operating loss for the quarter ended June 30, 2020 was $1.9 million compared to a loss of $1.9 million for the comparable 2019 period. For the six-month period ended June 30, 2020, the operating loss was $3.9 million versus $4.4 million for the six months ended June 30, 2019. The decrease in operating loss for 2020 was primarily due to a decrease in R&D expenses as we continue to wind down the clinical programs. This decrease was partially offset by an increase in G&A expenses which reflects an enhanced management structure to support corporate objectives as compared to the same period of 2019.

Net Loss: Net loss for the quarter ended June 30, 2020 was $2.0 million, or $0.15 per share, compared to a loss of $1.4 million, or $1.45 per share on a post-reverse stock-split basis, for the same period in 2019. For the 2020 six-month period the net loss was $9.5 million, or $0.92 per share versus a net loss of $4.6 million, or $4.78 per share for the same period in 2019. The 2020 increase in net loss was primarily attributed to a non-cash expense of $5.6 million related to the January 2020 warrant inducement transaction.

Prescient partners with global cancer heavyweight to develop new treatments

On August 14, 2020 Prescient Therapeutics (ASX:PTX) reported that it has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre, ‘Peter Mac’, a leader in new clinical treatments for cancer to develop CAR-T cell therapy technologies (Press release, Prescient Therapeutics, AUG 14, 2020, View Source;utm_medium=rss&utm_campaign=prescient-partners-with-global-cancer-heavyweight-to-develop-new-treatments [SID1234565488]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research program is being led by Professor Phil Darcy, head of cancer immunotherapy at Peter Mac’s Melbourne laboratory and will seek to produce technologies that can complement existing CAR-T cancer treatment approaches.

Prescient is the only ASX company that is developing CAR-T programs and it will own the intellectual property rights stemming from the research program.

The company’s CAR-T cancer treatment reprograms the Chimeric Antigen Receptors (CAR) on the outside of T-Cells to enable them to better target and eradicate cancer cells within patients.

Prescient Therapeutics chief executive Steven Yatomi-Clarke said the company’s research partnership with Peter Mac would greatly enhance efforts to advance new cancer treatments that would benefit patients.

"We look forward to working closely with Peter Mac as we employ our knowledge of targeted therapies and growing standing in cellular therapies to generate technologies that will be relevant for the CAR-T field," Yatomi-Clarke said.

Peter Mac research will advance PTX’s treatments
The research program at Peter Mac is an important addition to the Cell Therapy Enhancements (CTE) programs in Prescient’s treatments pipeline.

Prescient develops personalised medical approaches to cancer including targeted and cellular therapies such as its OmniCar immune receptor platform, an advanced version of CAR-T cancer treatment.

The company’s CTE programs aim to create efficacy and efficiency enhancements that are relevant to third parties in the cell therapy field, namely CAR-T, which may incorporate these into their own programs under licence.

Professor Darcy said the research with Prescient aimed to reprogram the microenvironment of cancer tumours to achieve better results with the CAR-T therapy.

"CAR-T therapy has shown strong therapeutic activity in certain haematological malignancies, however, the effects in solid cancers have been poor to date," he said.

"The approach we are exploring with Prescient may reprogram the tumour microenvironment that results in significantly enhancing CAR-T cell anti-tumour activity."

Boosting the coffers by $6.5m
Prescient has launched a capital raising for $6.5m via a share purchase plan to fund the expansion of its line of cancer treatments, including clinical trials of its PTX 100 and 200 products, and OmniCAR platform.

The SPP share issue is priced at 5.5c, a 15 per cent discount to its volume-weighted average share price prior to the SPP announcement, and it closes August 17.

VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

On August 13, 2020 VBL Therapeutics (Nasdaq: VBLT) reported financial results for the second quarter ended June 30, 2020, and provided a corporate update (Press release, VBL Therapeutics, AUG 13, 2020, View Source [SID1234563568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have made excellent progress advancing our lead candidate VB-111 during 2020," said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. "The first interim analysis in our OVAL Phase 3 pivotal study in ovarian cancer demonstrated the potential benefit of VB-111 over standard-of-care in a randomized-controlled study, and the recent positive second interim analysis indicates that the trial continues to be on the right track. OVAL has shown strong recruitment despite the COVID-19 pandemic. Also, when the Company blindly reviews response rate data in all trial participants, that is in the treatment and control groups combined, we are very encouraged by the high response rate of over 50% of the total evaluable patients, which has been maintained. The investigator sponsored studies of VB-111 in GBM and colorectal cancer are headed for initiation. Our MOSPD2 programs are gaining momentum, with pre-IND application for our lead candidate VB-601 for inflammation, and recent scientific presentations in NASH and colitis at DDW, in rheumatoid arthritis at EULAR 2020 and in oncology at the AACR (Free AACR Whitepaper) meeting."

Second Quarter and Recent Key Corporate Highlights:

VB-111

●Efficacy data from first interim analysis in the OVAL were reported in March and presented at the ASCO (Free ASCO Whitepaper)20 Annual Meeting, showing 58% or higher objective response rate.

oOVAL independent DSMC reviewed unblinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC recommended that the study proceed without modification.

oOverall response rate in the first 60 randomized evaluable patients was 53%. Assuming a balanced randomization, it can be deduced that the response rate in the treatment arm (VB-111 in addition to weekly paclitaxel) was 58% or higher.

oIn patients with post-treatment fever, the response was 69%. Fever is frequently observed after VB-111 treatment.

●Successful second pre-planned interim analysis, with a positive DSMC review of OS data, the primary endpoint of the OVAL Phase 3 potential registration study, was completed on August 11.

oIndependent DSMC reviewed unblinded data of the first 100 patients with follow-up of at least 3 months and determined that the study should proceed without modification.

●Two investigator sponsored VB-111 Phase 2 studies, in rGBM, at Dana Farber Cancer Center and other leading neuro-oncology centers, and in metastatic colorectal cancer by the NCI, are on track for initiation.
MOSPD2

●Pre-IND application for VBL’s VB-601 mAb for immune-inflammatory indications was submitted to the FDA in June. The application is currently under review by the agency.

●Announced new data implicating the potential of its anti-MOSPD2 antibodies for treatment of nonalcoholic steatohepatitis (NASH) and colitis at DDW 2020.

oTreatment with anti-MOSPD2 antibodies was shown to decrease inflammation and fibrosis in a NASH model and significantly reduce disease activity in a colitis model. VBL’s study was rated in the top 10% of all abstracts in this category and was selected as Poster of Distinction.

●Presented new data at the European League Against Rheumatism (EULAR) implicating the potential of proprietary anti-MOSPD2 antibodies for treatment of rheumatoid arthritis (RA).

oTreatment with anti-MOSPD2 antibodies significantly inhibited arthritis progression in the collagen-induced arthritis model (p<0.005). The treatment reduced >50% of disease severity and blocked further disease progression.

oAnti-MOSPD2 demonstrated higher activity than anti-TNFa in the advanced phase of the disease.

●Published a new manuscript demonstrating the potential of MOSPD2 antibodies in multiple sclerosis (MS). The results add to a growing body of data demonstrated activity of VBL’s antibodies in models of chronic inflammatory disease.

●Presented new data demonstrating the potential of anti-MOSPD2 immune-mediated targeting of solid tumors at the Annual American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II.

oMOSPD2 bi-specific antibody candidates induced T-cell activation and significantly extended the survival of animals carrying established metastatic cervical and breast cancer.

oThe data presented demonstrated that the bi-specific antibody candidates mediated killing of tumor cells by CD8 T-cells in a dose-dependent manner and induced T-cell activation in-vivo.
VB-201

●The world-leading European animal health company partner, that is evaluating VB-201 for veterinary applications, advised that the program met a pre-determined milestone. This triggered an undisclosed cash payment to VBL.
Corporate:

●Raised $18.1 million of gross proceeds in two registered direct offerings

●Awarded a non-dilutive grant of up to 3.175 million New Israeli Shekels (NIS; approximately $0.9 million) by the Israel Innovation Authority (IIA).
Quarter Ended June 30, 2020 Financial Results:

●Cash Position: At June 30, 2020, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposit totaling $41.3 million and working capital of $36.1 million. VBL expects that its cash and cash equivalents and short-term bank deposits will be sufficient to fund operating expenses and capital expenditure requirements into the third quarter of 2022.

●Revenue: Revenues for the second quarter, 2020 were $158 thousand, compared to $138 thousand for the comparable period in 2019.

●Research and Development Expenses: Research and Development expenses, net, were approximately $4.9 million for the second quarter, compared to approximately $3.7 million in the comparable period of 2019.

●General and Administrative Expenses: General and administrative expenses for the second quarter were $1.1 million, compared to $1.2 million for the same period of 2019.

●Comprehensive Loss: VBL reported a net loss for three-month period ended June 30, 2020 of $5.8 million, or ($0.14) per diluted share, compared to a net loss of $4.7 million, or ($0.13) per diluted share, in the same period of 2019.
For further details on VBL’s financials, please refer to Form 6-k filed with the SEC.